Literature DB >> 300360

Immunoprotective activity of ribosomes from Haemophilus influenzae.

M Lynn, R P Tewari, M Solotorovsky.   

Abstract

Immunization with ribosomal preparations from Haemophilus influenzae type b elicited protective immunity in mice. Ribosomes from disrupted cells where isolated by differential centrifugation using sodium dodecyl sulfate. The washed ribosomes contained 25% protein and 75% ribonucleic acid and sedimented as a single peak on sucrose density gradient analysis with a sedimentation coefficient of 67S, using Escherichia coli ribosomes as a 70S marker. Immunodiffusion tests with antipolyribose phosphate serum showed that the ribosomes were free from capsular material. Mice immunized subcutaneously with ribosomes, with or without adjuvant, were challenged intraperitoneally with 100 to 1,000 mean lethal doses of H. influenzae type b suspended in gastric mucin. Significant protection was induced by ribosomes and was compared to that obtained after sublethal infection with live cells. The protection was greatly enhanced after incorporation of ribosomes into adjuvants. Maximum protection (90 to 95%) was observed at 1 to 2 weeks after immunization. Ribosomes from a nonencapsulated strain of H. influenzae were as immunogenic as those from the encapsulated strain, demonstrating that the capsular material is not responsible for immunogenicity of Haemophilus ribosomes.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 300360      PMCID: PMC421389          DOI: 10.1128/iai.15.2.453-460.1977

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Biological properties of an immunogenic pneumococcal subcellular preparation.

Authors:  H C Thompson; T K Eisenstein
Journal:  Infect Immun       Date:  1976-03       Impact factor: 3.441

2.  Humoral immunity to Streptococcus pneumoniae induced by a pneumococcal ribosomal protein fraction.

Authors:  C L Swendsen; W Johnson
Journal:  Infect Immun       Date:  1976-08       Impact factor: 3.441

3.  The critically ill child: management of acute bacterial meningitis.

Authors:  P F Wehrle; A W Mathies; J M Leedom
Journal:  Pediatrics       Date:  1969-12       Impact factor: 7.124

4.  Changing incidence of Hemophilus influenzae meningitis.

Authors:  E W Smith; R E Haynes
Journal:  Pediatrics       Date:  1972-11       Impact factor: 7.124

5.  Heteroimmunization to the capsular polysaccharide of Haemophilus influenzae type b induced by enteric cross-reacting bacteria.

Authors:  Z T Handzel; M Argaman; J C Parke; R Schneerson; J B Robbins
Journal:  Infect Immun       Date:  1975-05       Impact factor: 3.441

6.  Biochemical and immunological properties of ribonucleic acid-rich extracts from Francisella tularensis.

Authors:  I I Andron LA; H T Eigelsbach
Journal:  Infect Immun       Date:  1975-07       Impact factor: 3.441

7.  Ribosomal vaccines. II. Specificity of the immune response to ribosomal ribonucleic acid and protein isolated from Salmonella typhimurium.

Authors:  W Johnson
Journal:  Infect Immun       Date:  1973-09       Impact factor: 3.441

8.  Immunogenicity of ribosomal vaccines isolated from group A, type 14 Streptococcus pyogenes.

Authors:  W O Schalla; W Johnson
Journal:  Infect Immun       Date:  1975-06       Impact factor: 3.441

9.  Human serum activities against Hemophilus influenzae, type b.

Authors:  P Anderson; R B Johnston; D H Smith
Journal:  J Clin Invest       Date:  1972-01       Impact factor: 14.808

10.  Production of Haemophilus influenzae b meningitis in infant rats by intraperitoneal inoculation.

Authors:  A L Smith; D H Smith; D R Averill; J Marino; E R Moxon
Journal:  Infect Immun       Date:  1973-08       Impact factor: 3.441

View more
  18 in total

1.  Characterization of the immunoprotective antigen of ribosomal preparations from Haemophilus influenzae.

Authors:  R P Tewari; M Lynn; A J Birnbaum; M Solotorovsky
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

2.  Induction of active immunity with membrane fractions from Haemophilus influenzae type b.

Authors:  J P Burans; M Lynn; M Solotorovsky
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

3.  Direct evidence for the presence of lipopolysaccharide components in Pseudomonas ribosomal vaccine.

Authors:  M M Lieberman
Journal:  Infect Immun       Date:  1977-08       Impact factor: 3.441

4.  Role of outer envelope contamination in protection elicited by ribosomal preparations against Neisseria gonorrhoeae infection.

Authors:  M D Cooper; M J Wannemuehler; R D Miller; M F Fedyk
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

5.  Immunogenic capacity of ribosomes of Salmonella typhi interfered with a flagellin-like material contaminant.

Authors:  G Cofré; I Calderón; G C Mora
Journal:  Infect Immun       Date:  1978-04       Impact factor: 3.441

6.  Induction of immunity against lethal Haemophilus influenzae type b infection by Escherichia coli core lipopolysaccharide.

Authors:  M I Marks; E J Ziegler; H Douglas; L B Corbeil; A I Braude
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

7.  Capsular serotypic specificity of the protection conferred on mice by Klebsiella pneumoniae ribosomal preparations.

Authors:  M Riottot; J M Fournier; J Pillot
Journal:  Infect Immun       Date:  1979-05       Impact factor: 3.441

8.  Serological and biological activities of anti-Haemophilus influenzae ribosomal serum.

Authors:  M Katz; M Lynn; M Solotorovsky
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

9.  Kinetics of Haemophilus influenzae type B infection in normal and ribosome-immunized mice using intraperitoneal and intracerebral routes of inoculation.

Authors:  J P Burans; F H Kruszewski; M Lynn; M Solotorovsky
Journal:  Br J Exp Pathol       Date:  1981-10

10.  Humoral and cell-mediated responses to a ribosomal preparation from Streptococcus mutans.

Authors:  R L Gregory; I L Shechmeister
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.